Scant Funds, Rare Outbreaks Leave Ebola Drug Pipeline Slim

Almost 40 years after the Ebola virus was identified in humans by scientists in a microbiology laboratory in Belgium, pharmaceutical researchers have yet to develop an effective drug or vaccine to fight it. Part of the problem is that the deadly virus is rare and its victims are often poor people living in rural areas of Africa without well-functioning health systems. But there is also little incentive for major pharmaceutical companies to invest in medical solutions when there is little...

© La Voix de l'Amérique - vendredi 28 mars 2014